Pure Global AI
NCT06110676Recruiting

A Study to Evaluate the Efficacy and Safety of LZM012

A Muti-center, Randomized, Double Blind, Positive Control Phase III Clinical Study to Evaluate the Efficacy and Safety of LZM012 in Moderate to Severe Chronic Plaque Psoriasis Patients
Livzon Pharmaceutical Group Inc.Phase 3ClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Psoriasis
Drug/Device/Intervention
LZM012
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Livzon Pharmaceutical Group Inc.
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 3
Start date
Aug 21, 2023
End date
Jun 01, 2025
Enrollment
918 participants
Primary outcome

PASI100 response rate

Summary

This study is a muti-center, randomized, double blind, positive control phase III clinical
 study to evaluate the efficacy and safety of LZM012 in moderate to severe chronic plaque
 psoriasis patients

ICD-10 classifications
PsoriasisOther psoriasisPsoriasis, unspecifiedArthropathic psoriasisPsoriasis vulgaris
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06110676
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06110676 through Pure Global AI's free database. This Phase 3 trial is sponsored by Livzon Pharmaceutical Group Inc. and is currently Recruiting. The study focuses on Psoriasis. Target enrollment is 918 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.